Comparison of the Efficacy and Safety of Bexarotene and Photo(Chemo)Therapy Combination Therapy and Bexarotene Monotherapy for Cutaneous T-Cell Lymphoma
ConclusionBoth bexarotene and photo(chemo)therapy combination therapy and bexarotene monotherapy were therapeutically effective in Japanese patients with CTCL and well tolerated. Combination therapy led to a higher skin lesion resolution rate and greater therapeutic effects compared with monotherapy.Trial RegistrationjRCTs041180094. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 27, 2022 Category: Dermatology Source Type: research

Lentigo Maligna on a Difficult Location of the Face Treated with 5% Imiquimod: A Case Report of 2-Year Follow-Up
We present a case in which interval treatment with 5% topical imiquimod was implemented for severe inflammatory response. An 82-year-old Caucasian woman presented with a large, irregularly pigmented lesion on her left cheek within the scar of a previously excised melanocytic lesion diagnosed as junctional nevus. Based on dermatoscopical examination confirmed by histopathological description, lentigo maligna was diagnosed. Since the lesion was large and covered the lower left eyelid and due to the risk of disfigurement, the patient refused surgical excision. Therefore, treatment with imiquimod 5% once daily, five times per ...
Source: Dermatology and Therapy - January 26, 2022 Category: Dermatology Source Type: research

Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
We present the case of a 49-year-old female patient with diabetes and psoriasis and psoriatic arthritis treated with an adalimumab biosimilar who developed a severe PAE of the palmoplantar pustular type. Treatment with adalimumab was stopped and the patient switched to ixekizumab which was successful. When a paradoxical r eaction develops during biologic therapy, especially when it is severe as in our patient, switching to another class of biologics is advised. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 24, 2022 Category: Dermatology Source Type: research

Role of Interleukin 36 in Generalised Pustular Psoriasis and Beyond
This article provides an overview of the current evidence that supports the role of IL-36 as a central node cytokine in GPP pathogenesis. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 21, 2022 Category: Dermatology Source Type: research

Facial Acne: A Randomized, Double-Blind, Placebo-Controlled Study on the Clinical Efficacy of a Symbiotic Dietary Supplement
AbstractIntroductionTreatments other than topical and systemic antibiotics are needed to restore the dysbiosis correlated with acne onset and evolution. In this view, probiotics and botanical extracts could represent a valid adjunctive therapeutic approach. The purpose of this study was to test the efficacy of a dietary supplement containing probiotics (Bifidobacterium  breve BR03 DSM 16604,Lacticaseibacillus  casei LC03 DSM 27537, andLigilactobacillus  salivarius LS03 DSM 22776) and botanical extract (lupeol fromSolanum  melongena L. andEchinacea extract) in subjects with mild to moderate acne over an ...
Source: Dermatology and Therapy - January 21, 2022 Category: Dermatology Source Type: research

Role of Interleukin 36 in Generalised Pustular Psoriasis and Beyond
This article provides an overview of the current evidence that supports the role of IL-36 as a central node cytokine in GPP pathogenesis. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 21, 2022 Category: Dermatology Source Type: research

Facial Acne: A Randomized, Double-Blind, Placebo-Controlled Study on the Clinical Efficacy of a Symbiotic Dietary Supplement
AbstractIntroductionTreatments other than topical and systemic antibiotics are needed to restore the dysbiosis correlated with acne onset and evolution. In this view, probiotics and botanical extracts could represent a valid adjunctive therapeutic approach. The purpose of this study was to test the efficacy of a dietary supplement containing probiotics (Bifidobacterium  breve BR03 DSM 16604,Lacticaseibacillus  casei LC03 DSM 27537, andLigilactobacillus  salivarius LS03 DSM 22776) and botanical extract (lupeol fromSolanum  melongena L. andEchinacea extract) in subjects with mild to moderate acne over an ...
Source: Dermatology and Therapy - January 21, 2022 Category: Dermatology Source Type: research

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
AbstractIntroductionPatients with moderate-to-severe plaque psoriasis who experience poor clinical outcomes, including patients with obesity or prior treatment, need improved treatment options. Risankizumab specifically inhibits interleukin 23 and has demonstrated superior efficacy in active-comparator studies in patients with moderate-to-severe plaque psoriasis. We compared the efficacy of risankizumab with that of secukinumab across patient subgroups.MethodsSubgroup analyses using data from the phase 3 IMMerge study (NCT03478787) were performed. Efficacy in adults with moderate-to-severe psoriasis treated with risankizum...
Source: Dermatology and Therapy - January 20, 2022 Category: Dermatology Source Type: research

Validation of Patient Identification Algorithms for Atopic Dermatitis Using Healthcare Databases
ConclusionThe Modified algorithm can be used to identify pediatric AD populations using primary and secondary administrative data with acceptable sensitivity and specificity, but further modifications are needed to accurately identify adult patients with AD. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 18, 2022 Category: Dermatology Source Type: research

The Impact of Stress-Coping Strategies and the Severity of Psoriasis on Self-Esteem, Illness Acceptance and Life Satisfaction
ConclusionsHigher severity of psoriasis (PASI) and greater frequency of emotion-oriented stress-coping mechanisms (CISS) are factors that negatively affect the overall psychophysical condition of respondents. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 18, 2022 Category: Dermatology Source Type: research

Validation of Patient Identification Algorithms for Atopic Dermatitis Using Healthcare Databases
ConclusionThe Modified algorithm can be used to identify pediatric AD populations using primary and secondary administrative data with acceptable sensitivity and specificity, but further modifications are needed to accurately identify adult patients with AD. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 18, 2022 Category: Dermatology Source Type: research

The Impact of Stress-Coping Strategies and the Severity of Psoriasis on Self-Esteem, Illness Acceptance and Life Satisfaction
ConclusionsHigher severity of psoriasis (PASI) and greater frequency of emotion-oriented stress-coping mechanisms (CISS) are factors that negatively affect the overall psychophysical condition of respondents. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 18, 2022 Category: Dermatology Source Type: research

Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study
AbstractIntroductionSecukinumab has demonstrated sustained long-term efficacy with a favourable safety profile in various manifestations of psoriatic disease. We investigated effectiveness and safety of secukinumab, other biologics and conventional systemic therapies in patients with chronic plaque psoriasis in a real-world setting.MethodsREALIA was a non-interventional, multicentre, prospective, parallel group study. Eligible patients were  ≥ 18 years old with chronic plaque psoriasis commencing a new treatment with a biologic agent or conventional systemic therapies.ResultsAt baseline, 541 patients ...
Source: Dermatology and Therapy - January 17, 2022 Category: Dermatology Source Type: research

Topical Ectoine Application in Children and Adults to Treat Inflammatory Diseases Associated with an Impaired Skin Barrier: A Systematic Review
ConclusionEctoine is an effective natural substance with an excellent tolerability and safety profile, representing a beneficial alternative as basic therapy or to increase the efficacy of the pharmacological treatment regimen for patients with inflammatory skin diseases, including infants and children. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 17, 2022 Category: Dermatology Source Type: research

Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study
AbstractIntroductionSecukinumab has demonstrated sustained long-term efficacy with a favourable safety profile in various manifestations of psoriatic disease. We investigated effectiveness and safety of secukinumab, other biologics and conventional systemic therapies in patients with chronic plaque psoriasis in a real-world setting.MethodsREALIA was a non-interventional, multicentre, prospective, parallel group study. Eligible patients were  ≥ 18 years old with chronic plaque psoriasis commencing a new treatment with a biologic agent or conventional systemic therapies.ResultsAt baseline, 541 patients ...
Source: Dermatology and Therapy - January 17, 2022 Category: Dermatology Source Type: research

Topical Ectoine Application in Children and Adults to Treat Inflammatory Diseases Associated with an Impaired Skin Barrier: A Systematic Review
ConclusionEctoine is an effective natural substance with an excellent tolerability and safety profile, representing a beneficial alternative as basic therapy or to increase the efficacy of the pharmacological treatment regimen for patients with inflammatory skin diseases, including infants and children. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 17, 2022 Category: Dermatology Source Type: research

Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial
ConclusionDeucravacitinib treatment produced early response and similar trends in improvements across multiple efficacy assessments and QoL in moderate to severe plaque psoriasis. Deucravacitinib has the potential to become a promising new oral therapy for this condition.Trial RegistrationClinicalTrials.gov identifier; NCT02931838. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 13, 2022 Category: Dermatology Source Type: research

Dapsone in Hidradenitis Suppurativa: A Systematic Review
ConclusionOverall, the quality of evidence supporting the use of dapsone is weak. However, it is a well established treatment recommended in current, various national guidelines. There is a crucial need for well-designed randomized controlled trials to support its usage. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 8, 2022 Category: Dermatology Source Type: research

Current Methods and Caveats to Risk Factor Assessment in Cutaneous Squamous Cell Carcinoma (cSCC): A Narrative Review
AbstractCutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer, and the number of deaths due to cSCC is estimated to be greater than the number attributed to melanoma. While the majority of cSCC tumors are resectable with clear margins by standard excision practices, some lesions exhibit high-risk factors for which there is evidence of their association with recurrence, metastasis, and disease-specific death. The most  commonly used staging systems and guidelines in the USA for cSCC are based on these clinical and pathologic high-risk factors; however, these are limited i...
Source: Dermatology and Therapy - January 7, 2022 Category: Dermatology Source Type: research

Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1  Year
Video (MP4 113130  kb) (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 7, 2022 Category: Dermatology Source Type: research

Current Methods and Caveats to Risk Factor Assessment in Cutaneous Squamous Cell Carcinoma (cSCC): A Narrative Review
AbstractCutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer, and the number of deaths due to cSCC is estimated to be greater than the number attributed to melanoma. While the majority of cSCC tumors are resectable with clear margins by standard excision practices, some lesions exhibit high-risk factors for which there is evidence of their association with recurrence, metastasis, and disease-specific death. The most  commonly used staging systems and guidelines in the USA for cSCC are based on these clinical and pathologic high-risk factors; however, these are limited i...
Source: Dermatology and Therapy - January 7, 2022 Category: Dermatology Source Type: research

Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1  Year
Video (MP4 113130  kb) (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 7, 2022 Category: Dermatology Source Type: research

Correction to: Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey
(Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 6, 2022 Category: Dermatology Source Type: research

Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management
The objective of this report was to combine results from published literature with experiences and recommendations from multiple investigators and institutions into clinical best pra ctice recommendations to assist healthcare providers in identifying and managing mogamulizumab-associated rash. Optimal management, which includes biopsy confirmation and steroid treatment, requires a multidisciplinary approach among oncology, dermatology, and pathology practitioners.Infographic (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 1, 2022 Category: Dermatology Source Type: research

Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16
ConclusionBaseline BSA of 10 –50% and early clinical improvement after 4 or 8 weeks of baricitinib 2-mg treatment may identify patients most likely to benefit from long-term baricitinib 2-mg therapy.Clinical Trial RegistrationNCT03435081. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 1, 2022 Category: Dermatology Source Type: research

Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy
ConclusionClinically meaningful improvements in signs and symptoms of PSO were maintained through week 52 for CZP dosed at 400  mg Q2W or 200 mg Q2W, across patient subgroups. In general, a numerically greater response was observed for patients receiving CZP 400 mg Q2W versus those receiving CZP 200 mg Q2W across patient subgroups.Trial RegistrationClinicalTrials.gov identifier, NCT03051217. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 1, 2022 Category: Dermatology Source Type: research

Arthritis Interception in Patients with Psoriasis Treated with Guselkumab
(Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 1, 2022 Category: Dermatology Source Type: research

Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) Questionnaire in Adults and Adolescents with Alopecia Areata
The objective of this study was to evaluate psychometric properties and establish scoring of the AAPPO in adults and adolescents with AA.MethodsScoring and measurement properties of the AAPPO were examined using baseline and 2-week follow-up data from a prospective, noninterventional, web-based study of 121 patients with AA (85 adults aged  ≥ 18 years, 36 adolescents aged 12–17 years) with Severity of Alopecia Tool (SALT) ≥ 25% scalp hair loss.ResultsExploratory and confirmatory factor analysis supported four single Hair Loss (HL) items, an Emotional Symptoms domain (ES; 4 ...
Source: Dermatology and Therapy - January 1, 2022 Category: Dermatology Source Type: research

Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management
The objective of this report was to combine results from published literature with experiences and recommendations from multiple investigators and institutions into clinical best pra ctice recommendations to assist healthcare providers in identifying and managing mogamulizumab-associated rash. Optimal management, which includes biopsy confirmation and steroid treatment, requires a multidisciplinary approach among oncology, dermatology, and pathology practitioners.Infographic (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 1, 2022 Category: Dermatology Source Type: research

Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16
ConclusionBaseline BSA of 10 –50% and early clinical improvement after 4 or 8 weeks of baricitinib 2-mg treatment may identify patients most likely to benefit from long-term baricitinib 2-mg therapy.Clinical Trial RegistrationNCT03435081. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 1, 2022 Category: Dermatology Source Type: research

Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy
ConclusionClinically meaningful improvements in signs and symptoms of PSO were maintained through week 52 for CZP dosed at 400  mg Q2W or 200 mg Q2W, across patient subgroups. In general, a numerically greater response was observed for patients receiving CZP 400 mg Q2W versus those receiving CZP 200 mg Q2W across patient subgroups.Trial RegistrationClinicalTrials.gov identifier, NCT03051217. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 1, 2022 Category: Dermatology Source Type: research

Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52  Weeks
ConclusionsIn adult patients with moderate-to-severe AD, treatment with dupilumab resulted in rapid and sustained improvement in the signs of AD across all anatomic regions.Trial registrationLIBERTY AD CHRONOS (NCT02260986). (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 1, 2022 Category: Dermatology Source Type: research

Arthritis Interception in Patients with Psoriasis Treated with Guselkumab
(Source: Dermatology and Therapy)
Source: Dermatology and Therapy - January 1, 2022 Category: Dermatology Source Type: research

Ixekizumab 80  mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis
ConclusionsThis study indicates that ixekizumab continuous Q2W dosing is efficacious and safe for patients with GPP and EP.Clinical Trial RegistrationNCT03942042. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - December 29, 2021 Category: Dermatology Source Type: research

Intensity of Local Skin Reactions During 5-Fluorouracil Treatment Related to the Number of Actinic Keratosis Lesions: A Post Hoc, Exploratory Analysis
This study aimed to examine the relationship between the severity of local skin reactions during treatment with 5-fluorouracil 4% cream and the number of AK lesions at baseline.MethodsThis post hoc analysis pooled data from two multicentre randomised phase  III studies (HD-FUP3B-048, HD-FUP3B-049) in patients with AK treated with topical 5-fluorouracil 4% once daily (OD) or 5% twice daily (BID) for 4 weeks. First, we compared the severity, assessed using a numerical rating scale, of the local skin reactions between 5-fluorouracil 4% and 5%. Then, we investigated the relationship between the number of lesions at b...
Source: Dermatology and Therapy - December 26, 2021 Category: Dermatology Source Type: research

Apremilast Prolongs the Time to First Biologic Therapy in Japanese Patients with Psoriasis
The objective of this study was to assess whether apremilast can prolong time to first biologic therapy use and decrease total medical cost.MethodsUsing the Medical Data Vision hospital-based claims database, 506 psoriasis patients were propensity score matched and analyzed (apremilast:n = 253; non-apremilast:n = 253).ResultsThe incidence rate of first biologic therapy use per 1000 patient-years was significantly lower in the apremilast group than in the non-apremilast group (30.3 vs. 107.6;P 
Source: Dermatology and Therapy - December 24, 2021 Category: Dermatology Source Type: research

Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test for Improved Patient Management Decisions and Disease-Related Outcomes when Combined with Current Clinicopathological Risk Factors for Cutaneous Squamous Cell Carcinoma (cSCC): Case Series
ConclusionsThe cases discussed highlight the utility in 40-GEP to provide additional information to guide treatment decisions and improve outcomes. Integrating novel molecular prognostication with traditional clinicopathological risk factors can improve stratification of high-risk cSCC patients and may inform selection of risk-appropriate treatment and surveillance strategies. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - December 23, 2021 Category: Dermatology Source Type: research

Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology
ConclusionThrough this novel approach, we will derive practical, informative recommendations using the best evidence available in combination with structured expert opinion to guide best practices in complex, real-world settings.Supplementary file2 (MP4 98653  kb) (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - December 22, 2021 Category: Dermatology Source Type: research

Methoxy-Monobenzoylmethane Protects Skin from UV-Induced Damages in a Randomized, Placebo Controlled, Double-Blinded Human In Vivo Study and Prevents Signs of Inflammation While Improving the Skin Barrier
ConclusionBased on these results, MeO-MBM is capable of exerting an anti-aging activity via the retinoic acid receptor gamma. Its anti-inflammatory and anti-oxidative activity manifested via the downregulation of multiple anti-inflammatory genes as well as the reduction of ferritin in skin tissue. This study shows that the multidimensional functionality of MeO-MBM offers an effective approach to combat acute and chronic deleterious effects of oxidative UV damage while simultaneously enhancing the skin barrier function. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - December 22, 2021 Category: Dermatology Source Type: research

Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology
ConclusionThrough this novel approach, we will derive practical, informative recommendations using the best evidence available in combination with structured expert opinion to guide best practices in complex, real-world settings.Supplementary file2 (MP4 98653  kb) (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - December 22, 2021 Category: Dermatology Source Type: research

Methoxy-Monobenzoylmethane Protects Skin from UV-Induced Damages in a Randomized, Placebo Controlled, Double-Blinded Human In Vivo Study and Prevents Signs of Inflammation While Improving the Skin Barrier
ConclusionBased on these results, MeO-MBM is capable of exerting an anti-aging activity via the retinoic acid receptor gamma. Its anti-inflammatory and anti-oxidative activity manifested via the downregulation of multiple anti-inflammatory genes as well as the reduction of ferritin in skin tissue. This study shows that the multidimensional functionality of MeO-MBM offers an effective approach to combat acute and chronic deleterious effects of oxidative UV damage while simultaneously enhancing the skin barrier function. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - December 22, 2021 Category: Dermatology Source Type: research